IPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer

Prostate

Volumn 61, Issue 3, 2004, Pages 248-252

  Yokomizo, Akira ^a   Koga, Hirofumi ^a   Kinukawa, Naoko ^a   Tsukamoto, Taiji ^b   Hirao, Yoshihiko ^c   Akaza, Hideyuki ^d   Mori, Mitsuru ^b   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

HPC2 ELAC2; Polymorphism; Prostate cancer; SNP

Indexed keywords

ALLELE; ARTICLE; ASIAN AMERICAN; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FAMILIAL CANCER; FISHER EXACT TEST; GENOTYPE; HUMAN; LINKAGE ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANK SUM TEST; RISK; UNITED STATES; AGED; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; JAPAN; MIDDLE AGED; PREDICTION AND FORECASTING; PROSTATE TUMOR; RISK FACTOR;

ELAC2 PROTEIN, HUMAN; TUMOR PROTEIN;

AGED; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 5344271259     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20107     Document Type: Article

References (29)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1997;47:5-27.
2. Sasagawa I, Nakada T. Epidemiology of prostatic cancer in East Asia. Arch Androl 2001;47:195-201.
3. Taylor JD, Holmes TM, Swanson GM. Descriptive epidemiology of prostate cancer in metropolitan Detroit. Cancer 1994;73:1704-1707.
4. Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2002;12:182-196.
5. Ross R, Pike M, Coetzee G, Reichardt J, Yu M, Feigelson H, Stanczyk F, Kolonel L, Henderson B. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. Cancer Res 1998;58:4497-4504.
6. Ingles S, Ross R, Yu M, Irvine R, La Pera G, Haile R, Coetzee G. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-170.
7. Febbo P, Kantoff P, Giovannucci E, Brown M, Chang G, Hennekens C, Stampfer M. Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer Epidemiol Biomarkers Prev 1998;7: 1075-1078.
8. Murata M, Shiraishi T, Fukutome K, Watanabe M, Nagao M, Kubota Y, Ito H, Kawamura J, Yatani R. Cytochrome P4501A1and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan. Jpn J Clin Oncol 1998;28:657-660.
9. Rebbeck T, Jaffe J, Walker A, Wein A, Malkowicz S. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90:1225-1229.
10. Giovannucci E, Stampfer M, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens C, Kantoff P. The CAG repeatwithin the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94:3320-3323.
11. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, Katoh T, Kamataki T, Kawamura J, Yatani R, Shirashi T. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1, and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001;165:171-177.
12. Makridakis N, Ross R, Pike M, Crocitto L, Kolonel L, Pearce C, Henderson B, Reichardt J. Association of mis-sense substitution of SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975-978.
13. Elkins DA, Yokomizo A, Thibodeau SN, J Schaid D, Cunningham JM, Marks A, Christensen E, McDonnell SK, Slager S, J Peterson B, J Jacobsen S, R Cerhan J, L Blute M, J Tindall D, Liu W. Luteinizing hormone beta polymorphism and risk of familial and sporadic prostate cancer. Prostate 2003;56:30-36.
14. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001;27:172-180.
15. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, Wein AJ, Malkowicz SB. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000;67:1014-1019.
16. Sobin LH, Wittekind C. International Union Against Cancer. Urological tumours. TNM Classification of Malignant Tumours, 5th edn. New York: Wiley-Liss; 1997. pp 170-173.
17. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 1994;74:104-114.
18. Gleason DF. Histological grading and clinical staging of prostatic carcinoma, Philadelphia: Lea & Febiger; 1977. pp 171-197.
19. Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK, Catalona WJ. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 2001;61:4982-4984.
20. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 2001;61:6494-6499.
21. Vesprini D, Nam RK, Trachtenberg J, Jewett MA, Tavtigian SV, Emami M, Ho M, Toi A, Narod SA. HPC2 variants and screen-detected prostate cancer. Am J Hum Genet 2001;68:912-917.
22. Rokman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res 2001;61:6038-6041.
23. Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, Moses TY, Faith DA, Kelly BD, Isaacs SD, Wiley KE, Ewing CM, et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 2001;68:901-911.
24. Severi G, Giles GG, Southey MC, Tesoriero A, Tilley W, Neufing P, Morris H, English DR, McCredie MR, Boyle P, Hopper JL. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. J Natl Cancer Inst 2003;95:818-824.
25. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, Jiang R, Messer CJ, Chew A, Han JH, Duan J, Carr JL, Lee MS, Koshy B, Kumar AM, Zhang G, Newell WR, Windemuth A, Xu C, Kalbfleisch TS, Shaner SL, Arnold K, Schulz V, Drysdale CM, Nandabalan K, Judson RS, Ruano G, Vovis GF. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001;293:489-493.
26. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-199.
27. Takahashi H, Lu W, Watanabe M, Katoh T, Furusato M, Tsukino H, Nakao H, Sudo A, Suzuki H, Akakura K, Ikemoto I, Asano K, Ito T, Wakui S, Muto T, Hano H. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men. Int J Cancer 2003;107:224-228.
28. Suzuki K, Ohtake N, Nakata S, Takei T, Matsui H, Ono Y, Nakazato H, Hasumi M, Koike H, Ito K, Fukabori Y, Kurokawa K, Yamanaka H. Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population. Anticancer Res 2002;22:3507-3511.
29. Fujiwara H, Emi M, Nagai H, Nishimura T, Konishi N, Kubota Y, Ichikawa T, Takahashi S, Shuin T, Habuchi T, Ogawa O, Inoue K, Solnick MH, Swensen J, Camp NJ, Tavtigian SV. Association of common missense changes in ELAC2 (HPC2) with prostate cancer in a Japanese case-control series. J Hum Genet 2002;47: 641-648.